Insider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells 407,000 Shares of Stock

ADMA Biologics, Inc. (NASDAQ:ADMAGet Free Report) Director Steve Elms sold 407,000 shares of ADMA Biologics stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the transaction, the director now directly owns 3,208,671 shares of the company’s stock, valued at $19,925,846.91. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Steve Elms also recently made the following trade(s):

  • On Friday, March 15th, Steve Elms sold 183,008 shares of ADMA Biologics stock. The shares were sold at an average price of $6.01, for a total transaction of $1,099,878.08.

ADMA Biologics Trading Down 0.5 %

Shares of NASDAQ:ADMA traded down $0.03 during trading on Friday, hitting $5.99. 3,750,686 shares of the company’s stock were exchanged, compared to its average volume of 2,783,225. ADMA Biologics, Inc. has a 1-year low of $2.94 and a 1-year high of $6.41. The firm has a 50-day moving average price of $5.37 and a two-hundred day moving average price of $4.32. The company has a current ratio of 5.16, a quick ratio of 1.69 and a debt-to-equity ratio of 1.04. The firm has a market cap of $1.37 billion, a P/E ratio of -46.08 and a beta of 0.43.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ADMA. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of ADMA Biologics in a report on Thursday, February 29th. Cantor Fitzgerald boosted their target price on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Mizuho boosted their target price on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $7.50.

View Our Latest Stock Report on ADMA

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors have recently modified their holdings of ADMA. JPMorgan Chase & Co. grew its holdings in ADMA Biologics by 360.0% during the first quarter. JPMorgan Chase & Co. now owns 79,106 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 61,909 shares during the period. Raymond James & Associates grew its holdings in ADMA Biologics by 24.0% during the first quarter. Raymond James & Associates now owns 199,984 shares of the biotechnology company’s stock valued at $366,000 after purchasing an additional 38,715 shares during the period. Bank of New York Mellon Corp grew its holdings in ADMA Biologics by 79.6% during the first quarter. Bank of New York Mellon Corp now owns 83,401 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 36,967 shares during the period. Bank of Montreal Can acquired a new position in ADMA Biologics during the first quarter valued at approximately $1,665,000. Finally, BlackRock Inc. boosted its holdings in shares of ADMA Biologics by 0.8% in the first quarter. BlackRock Inc. now owns 4,107,382 shares of the biotechnology company’s stock valued at $7,517,000 after buying an additional 31,791 shares during the period. Institutional investors and hedge funds own 73.58% of the company’s stock.

About ADMA Biologics

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Further Reading

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.